Melanotan 1 vs PT-141
Updated 7 sources
Key differences
- 1Both share melanocortin ancestry with MT2. PT-141 targets desire (MC3R/MC4R) and tans minimally; MT1 prefers MC1R, the pigment receptor.
- 2Each has one approval: Scenesse for EPP, Vyleesi for low sexual desire in women.
Side by side
Facts from each record, in the same words as their own pages.
| Melanotan 1 | PT-141 | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
7 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study1
- Ugwu SO et al. 1997, skin pigmentation and pharmacokinetics of melanotan-I in humans, Biopharm Drug DisposPubMed · checked Oct 24, 2026
Regulatory5
- Scenesse (afamelanotide) implant prescribing information, current labelDailyMed · checked Oct 24, 2026
- Vyleesi (bremelanotide) prescribing information, 2019FDA · checked Oct 23, 2026
- WADA 2026 Prohibited ListWADA · checked Oct 24, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · checked Oct 24, 2026
Competitor guide1
- Melanotan 2 (MT-2) Peptide Guide (MT-2 vs PT-141 vs afamelanotide)peptidedosingprotocols.com · checked Oct 24, 2026